The licence expressly covers three African territories (South Africa, Kenya, Nigeria), which is a qualifying territorial nexus even though neither contracting party is African-domiciled.
| Record ID | TX-AFR-2025-0002 |
|---|---|
| Record type | Commercial IP transaction |
| Transaction type | Patent licence, Exclusive licence, In-licensing |
| IP rights | patent, regulatory data, trade mark |
| Status | Signed |
| Qualifying date | 2025-03-18 |
| Sector | Life sciences · Pharmaceuticals – ophthalmology |
| African markets | South Africa, Kenya, Nigeria |
| Licensed territory | Eleven countries: India, South Africa, Nepal, Sri Lanka, Bangladesh, Malaysia, Myanmar, Kenya, Nigeria, Argentina and Colombia. |
| Disclosed value | Not disclosed in the sources reviewed. |
| Evidence | Primary source, independently corroborated · 2 source(s) |
| Last verified | 2026-10-25 |
Parties
- Cipla (India): licensee
- Formosa Pharma (Taiwan): licensor
Key terms
- Interest: exclusive licence to commercialise; Exclusivity: exclusive; Territorial scope: 11 countries (see licensed_territories); Term: Not stated in source; Field of use: Post-operative inflammation and pain following ocular surgery
- Financial terms as reported: “includes upfront payments, royalty milestones, and additional value-driven considerations throughout its term”
Sources
- Cipla and Formosa sign multi-regional licensing deal for Clobetasol Suspension, Cipla Limited, 2025-03-18
- Formosa Pharmaceuticals enters into licensing agreement with Cipla for commercialization of APP13007 across 11 countries, Modern Retina, 2025-05-08
Part of The Meridian’s Africa IP database. Counts, market breakdowns and rankings are derived from published records only; a record counts once. Corrections: submit evidence.
